Triple Combination Works Well in Recurrent Ovarian Cancer with Smaller Tumors, Study Shows

Triple Combination Works Well in Recurrent Ovarian Cancer with Smaller Tumors, Study Shows
The size of tumors in patients with recurrent ovarian cancer seems to predict responses to a triple combination treatment composed of IMV's lead candidate DPX-SurvivacIncyte's experimental epacadostat, and low-dose chemotherapy, a Phase 1/2 trial shows. Among patients with smaller tumors at baseline — 5 centimeters or less — the treatment reduced tumors in 67% and controlled the disease in an additional 16%. The findings were presented at the ESMO Immuno-Oncology 2018 Congress in Geneva, Switzerland, in a poster titled "New clinical data from the DeCidE1 trial: Results on DPX-Survivac, low dose cyclophosphamide (CPA), and epacadostat (INCB024360) in subjects with advanced recurrent epithelial ovarian cancer." DPX-Survivac is a cancer vaccine made of small fractions of the survivin protein. This protein is found is most cancer types at much higher levels than normal and plays a key role in supporting tumor blood vessel growth and promoting resistance to anti-cancer therapies. The therapy, administered as an injection under the skin, works by triggering a strong immune response against c
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *